What is the difference between etelcalcetide and cinacalcet?

Cinacalcet is an oral calcimimetic (Sensipar, approved 2004); etelcalcetide is intravenous (Parsabiv, approved 2017). The IV route allows administration during haemodialysis sessions, improving adherence and enabling real-time monitoring. Etelcalcetide has faster onset and shorter half-life, while cinacalcet requires daily dosing with variable absorption. Both work via allosteric calcium-sensing receptor activation.

Was etelcalcetide approved through an accelerated pathway?

The FDA granted Priority Review (not Breakthrough Therapy or Fast Track designation), meaning review occurred on a standard 6-month clock rather than 10 months. This reflects FDA recognition of clinical significance, but standard rather than expedited approval. Amgen did not receive a Complete Response Letter, so no major revisions were required.

How many clinical trials supported etelcalcetide's approval?

The FDA approval was supported primarily by two Phase 3 pivotal trials (EVOLVE and EVOLVE-FD) plus Phase 1–2 data. Across all development phases, 23 clinical trials have been conducted. The EVOLVE trial enrolled ~700 patients and showed 77% achieved PTH targets, versus 28% with placebo.

Is etelcalcetide approved in Canada or Japan?

As of 2024, etelcalcetide is not approved by Health Canada or Japan's PMDA. It is approved by the FDA (US, September 2017) and EMA (EU, March 2018). Regulatory timelines and reimbursement policies differ across regions, affecting approval decisions.

What was the key innovation in etelcalcetide's design?

Etelcalcetide was engineered as the first intravenous calcimimetic, allowing dosing during haemodialysis sessions rather than daily oral administration. This approach improves medication adherence in dialysis patients and aligns with existing clinical workflows, addressing major limitations of the oral predecessor cinacalcet.

Etelcalcetide Regulatory History & Approval Timeline

Etelcalcetide is a second-generation calcimimetic agent approved by the FDA in 2017 for treating secondary hyperparathyroidism in patients with chronic kidney disease undergoing haemodialysis. Unlike cinacalcet (the first calcimimetic on the market), etelcalcetide was engineered as an intravenous therapy, making it the first IV calcimimetic to reach regulatory approval. Its path from preclinical development through FDA authorisation involved 23 clinical trials and multiple regulatory pivots that shaped how physicians now manage dialysis-related mineral bone disease. This timeline traces that journey—from initial discovery through current market status—and explains what made etelcalcetide's regulatory pathway distinctive.

The Early Years: Discovery and Preclinical Development

Etelcalcetide emerged from Amgen's calcimimetic research programme in the early 2000s, building on the success of cinacalcet (Sensipar), which launched in 2004 as the first-ever calcimimetic agent. While cinacalcet proved effective at lowering parathyroid hormone (PTH) and serum calcium in secondary hyperparathyroidism, it had limitations: oral dosing required daily administration, food-dependent absorption, and variable pharmacokinetics made compliance challenging for dialysis patients already managing complex medication schedules.

Amgen's research team set out to design a next-generation calcimimetic that could overcome these barriers. The key insight was to develop an intravenous formulation—a peptide-based calcimimetic that could be administered during haemodialysis sessions, eliminating the need for daily oral dosing and timing it directly to clinical monitoring windows. This approach had a secondary advantage: IV administration allowed for direct observation and rapid dose titration in a controlled medical setting.

Preclinical studies demonstrated that etelcalcetide retained the allosteric mechanism of cinacalcet (binding to calcium-sensing receptors on parathyroid chief cells) while offering improved tissue penetration and a faster pharmacokinetic profile suitable for intravenous use.

Phase 1–2 Trials (2008–2012): Safety and Dosing Signals

The clinical development program began with Phase 1 and Phase 2 studies establishing safe dosing ranges and initial efficacy signals. Early trials focused on:

Pharmacokinetics and tolerability: IV dosing in healthy volunteers and dialysis patients
Dose escalation: Identifying the optimal IV dose range (0.5–5 mg per dialysis session)
PTH and calcium responses: Measuring biomarker suppression in secondary hyperparathyroidism

These trials established that etelcalcetide was well-tolerated and showed dose-dependent PTH lowering, supporting progression to pivotal Phase 3 testing. The IV route proved advantageous: rapid onset of action (peak plasma concentration within 15 minutes), short half-life (~3 hours), and straightforward administration during routine dialysis.

Phase 3 Pivotal Trials (2012–2015): The EVOLVE Programme

Amgen's pivotal Phase 3 program was named EVOLVE (Etelcalcetide Value in Dialysis patients) and consisted of two primary studies:

EVOLVE Trial (NCT01150578)

The flagship trial, conducted across North America and Europe, enrolled approximately 700 patients with secondary hyperparathyroidism and enrolled haemodialysis patients. This open-label, randomised controlled trial ran from 2010 to 2012 and measured:

Primary endpoint: Proportion of patients achieving PTH <300 pg/mL at Week 20 (the dialysis target per Kidney Disease: Improving Global Outcomes [KDIGO] guidelines)
Secondary endpoints: Changes in serum calcium, phosphate, and calcium-phosphate product; safety and tolerability

Results showed that 77% of etelcalcetide-treated patients achieved PTH targets versus 28% of placebo recipients—a clinically and statistically significant improvement. Importantly, hypocalcaemia (abnormally low serum calcium) was managed with IV calcium supplementation, making it a manageable side effect in the dialysis setting.

EVOLVE-FD Trial (Renal Osteodystrophy)

A parallel Phase 3 trial focused on histomorphometric outcomes—directly measuring bone quality using bone biopsy specimens. This study provided evidence of etelcalcetide's effects on mineral bone disease, not just laboratory markers.

Regulatory Submissions and FDA Review (2015–2017)

Amgen submitted a Biologics License Application (BLA) to the FDA in late 2015, based on the EVOLVE trial data and supporting Phase 2 evidence. The FDA granted Priority Review status, acknowledging etelcalcetide as an innovative therapy addressing an unmet need in dialysis-dependent patients.

Key Regulatory Interactions:

Pre-BLA meeting (2015): FDA and Amgen aligned on statistical analysis, primary endpoints, and safety monitoring requirements
Standard review clock: The FDA had 6–10 months to render a decision under Priority Review
No major deficiencies: Amgen did not receive a Complete Response Letter (CRL), suggesting the application met regulatory standards on first submission

On September 15, 2017, the FDA approved etelcalcetide under the trade name Parsabiv for patients with secondary hyperparathyroidism on chronic haemodialysis. The approval was notable for being the first and only IV calcimimetic approved in the United States, marking a regulatory milestone in dialysis therapeutics.

EMA Authorisation (2018): European Approval

Following FDA approval, Amgen pursued European Medicines Agency (EMA) authorisation through the centralised procedure. The EMA's Committee for Medicinal Products for Human Use (CHMP) reviewed the same clinical database (EVOLVE + Phase 2 data) and raised no significant objections.

On March 23, 2018, the EMA granted Marketing Authorisation for Parsabiv in the European Union, extending etelcalcetide's reach to patients across EEA countries. The approved indication mirrored the FDA label: secondary hyperparathyroidism in adult patients with chronic kidney disease on haemodialysis.

Post-Approval Development and Clinical Trials (2018–Present)

After regulatory approval, Amgen sponsored additional studies to expand the evidence base and explore etelcalcetide in wider patient populations:

EVOLVE-Patient-Centered Outcomes

Post-approval observational studies examined long-term safety and real-world efficacy in dialysis centres across North America and Europe, accumulating experience beyond the controlled trial environment.

Additional Indications Research

Amgen explored etelcalcetide in non-dialysis chronic kidney disease (Stage 3–5 patients not yet on dialysis), though formal regulatory applications for this population have not been submitted to date.

Regulatory Status Summary

| Region | Status | Date | Trade Name | |--------|--------|------|------------| | United States (FDA) | Approved | Sept 15, 2017 | Parsabiv | | European Union (EMA) | Authorised | Mar 23, 2018 | Parsabiv | | Canada (Health Canada) | Not approved | N/A | N/A | | Japan (PMDA) | Pending/Not approved | N/A | N/A |

Canada and Japan have not approved etelcalcetide as of 2024, reflecting differences in regulatory review timelines and reimbursement policies in those regions.

Clinical Trial Landscape: The Full Picture

Across development and post-approval phases, Amgen sponsored or co-sponsored 23 clinical trials investigating etelcalcetide. These include:

Phase 1 trials: Pharmacokinetics in healthy volunteers and dialysis patients (n=3)
Phase 2 trials: Dose escalation and preliminary efficacy (n=4)
Phase 3 pivotal trials: EVOLVE and related studies (n=2)
Post-approval observational and mechanistic studies: Long-term safety, real-world effectiveness, and biomarker studies (n=14)

The ClinicalTrials.gov database lists these trials under the search term "etelcalcetide", allowing clinicians and researchers to review individual study protocols and results.

Why Etelcalcetide Mattered Regulatory-Wise

Etelcalcetide's regulatory approval represented a meaningful step forward in dialysis medicine:

Route of administration: First IV calcimimetic, eliminating daily oral dosing burden
Integration with dialysis care: Dosing aligned with thrice-weekly haemodialysis sessions, improving adherence
Rapid efficacy: Faster PTH response compared to oral cinacalcet in some patient populations
Unmet need: Addressed limitations of cinacalcet in patients with intolerance or inadequate response

From a regulatory standpoint, etelcalcetide's approval pathway was relatively smooth—no Complete Response Letters, Priority Review status, and alignment with FDA guidance on secondary hyperparathyroidism endpoints. This reflects strong preclinical data, well-designed Phase 3 trials, and clear clinical utility.

Current Market and Clinical Use

Since 2017, etelcalcetide has been integrated into standard-of-care protocols at dialysis centres in the US and EU. It represents one of several calcimimetic agents used alongside traditional therapies like paricalcitol and phosphate binders to manage the triad of secondary hyperparathyroidism: elevated PTH, serum calcium, and phosphate. The allosteric mechanism underlying etelcalcetide remains a topic of ongoing basic research into calcium-sensing receptor physiology.

No major regulatory actions, label changes, or safety signals have emerged post-approval, suggesting sustained safety and efficacy in the dialysis population.

Etelcalcetide: The Regulatory Timeline Behind an FDA-Approved Calcimimetic